Oncolytic adenovirus with enhanced replication properties comprising modifications in E1A, E3, and E4
US12365878B2 · kind B2 · utility
0Cited by
154References
35Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 9, 2020 |
| Grant date | Jul 22, 2025 |
| Priority date | — |
| Expiry date | Dec 4, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/10371
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Tumor-selective recombinant adenoviruses that possess deletions or modifications in the E3 region are described. Recombinant adenoviruses that express adenovirus death protein (ADP) but have a deletion of at least three of the remaining six E3 genes exhibit enhanced virus replication. The recombinant adenoviruses further include additional modifications to allow selective replication in tumor cells and to detarget viruses from the liver. Use of the recombinant adenoviruses for cancer treatment is described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.